Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
Ann Costello     66     Director Deepika Pakianathan, Ph.D.     61     Director Randal Scott, Ph.D.     68     Director Douglas M. VanOort     70     Director               Executive Officers Aaron Elliott, Ph.D. has served as our Chief Executive Officer and a member of our board of directors (our “ Board ”) since July 2026. Previously, Dr. Elliott served as Chief Executive Officer and a member of the board of directors of Freenome Holdings from April 2025 to July 2026. Prior to that, Dr. Elliott served as Chief Executive Officer and President of REALM IDx, Inc. from May 2021 until February 2025. Prior to that, Dr. Elliott served in several leadership roles at Ambry Genetics Corporation, including Chief Executive Officer from March 2016 to May 2021 and Chief Scientific Officer from March 2012 to August 2016. Dr. Elliott holds a Ph.D. in Genetics from the Sidney Kimmel Cancer Center at Thomas Jefferson University and a B.S.
This record is keyed to SEC CIK 0002145484 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 24 institutional-holder rows on these vehicles, under 24 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.